# GENMAB A/S

Summary updated: 2026-10-02T11:32:50.977585Z
Canonical: https://finbar.com/research/companies/genmab-a-s

## Overview

GENMAB A/S is a biotechnology company focused on discovering, developing, and commercializing antibody-based medicines for cancer and other serious diseases. Founded in Copenhagen in 1999, the company develops medicines using proprietary antibody technologies, including its DuoBody platform. [1](https://www.genmab.com/about/our-history) [2](https://www.genmab.com/antibody-science/antibody-technology-platforms)

Its portfolio includes EPKINLY/TEPKINLY (epcoritamab), developed with AbbVie, and Tivdak (tisotumab vedotin), developed with Pfizer. Genmab is headquartered in Denmark and has an international presence across North America, Europe, and Asia Pacific. [3](https://app.finbar.com/go?id=P149982889) [4](https://www.genmab.com/contact)

Genmab describes its purpose as improving patients’ lives through innovative, differentiated antibody therapeutics. Its 2025 revenue was USD 3.72 billion for the year ended December 31, 2025; the company’s website reports a workforce of more than 3,000 employees. [5](https://www.genmab.com/about/our-purpose) [6](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231.htm)
[3](https://app.finbar.com/go?id=P149982889)[1](https://www.genmab.com/about/our-history)[2](https://www.genmab.com/antibody-science/antibody-technology-platforms)[4](https://www.genmab.com/contact)[5](https://www.genmab.com/about/our-purpose)[6](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231.htm)

## Products & services

Genmab’s marketed medicines include EPKINLY®/TEPKINLY® (epcoritamab), a CD3×CD20 bispecific antibody developed with AbbVie using Genmab’s DuoBody technology. Its listed approvals cover certain relapsed or refractory diffuse large B-cell and follicular lymphomas, including EPKINLY in combination with rituximab and lenalidomide for follicular lymphoma in the US. TIVDAK® (tisotumab vedotin), co-developed with Pfizer, is an antibody-drug conjugate approved for recurrent or metastatic cervical cancer after progression on or following prior systemic therapy. Genmab co-promotes TIVDAK in the US and leads operational activities in Japan. [7](https://app.finbar.com/go?id=T17158948)[8](https://app.finbar.com/go?id=P149983225)

Genmab also receives royalties on medicines marketed by partners: DARZALEX/DARZALEX FASPRO, RYBREVANT/RYBREVANT FASPRO, TECVAYLI and TALVEY from Johnson & Johnson; Kesimpta from Novartis; TEPEZZA from Amgen under a Roche sublicense; and BIZENGRI from Partner Therapeutics in the US. Their listed uses include multiple myeloma and AL amyloidosis, certain EGFR-mutated non-small cell lung cancers, relapsing multiple sclerosis, thyroid eye disease, and cancers with NRG1 gene fusions. [9](https://app.finbar.com/go?id=T17158950) Global EPKINLY/TEPKINLY net sales were $468 million in 2025 and $312 million in the first half of 2026; these are product sales, not Genmab-recognized revenue. [10](https://www.genmab.com/investor-relations/annual-report)[11](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2026)
[7](https://app.finbar.com/go?id=T17158948)[7](https://app.finbar.com/go?id=T17158948)[8](https://app.finbar.com/go?id=P149983225)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[9](https://app.finbar.com/go?id=T17158950)[10](https://www.genmab.com/investor-relations/annual-report)[11](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2026)[10](https://www.genmab.com/investor-relations/annual-report)[11](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2026)

## Geographic presence

Genmab’s listed facilities span Denmark (Valby and Ballerup), the Netherlands (Utrecht), the United States (Plainsboro, New Jersey), Japan (Tokyo), and China (Suzhou). [12](https://app.finbar.com/go?id=T17158952) In 2025, the company also established operations in France, the United Kingdom, and Germany. [13](https://www.genmab.com/news-insights/stories/delivering-genmabs-next-era-of-sustainable-growth)

Commercial activity is geographically divided among Genmab and its partners. For EPKINLY, Genmab shares U.S. and Japan commercial responsibilities with AbbVie; AbbVie handles commercialization elsewhere, where Genmab receives royalties. [14](https://app.finbar.com/go?id=P149984418)[15](https://app.finbar.com/go?id=P149984419)[16](https://app.finbar.com/go?id=P149984420)[17](https://app.finbar.com/go?id=P149984421)[18](https://app.finbar.com/go?id=P149984422)[19](https://app.finbar.com/go?id=P149984423)[20](https://app.finbar.com/go?id=P149984424)[21](https://app.finbar.com/go?id=P149984425)[22](https://app.finbar.com/go?id=P149984426) For Tivdak, Genmab co-promotes in the United States and leads commercial operations in Japan, Europe, and other regions except the United States and China; Pfizer leads U.S. commercial activity, and Zai Lab holds the China sublicense. [23](https://app.finbar.com/go?id=P149984427)[24](https://app.finbar.com/go?id=P149984428)[25](https://app.finbar.com/go?id=P149984429)[26](https://app.finbar.com/go?id=P149984430)[27](https://app.finbar.com/go?id=P149984431)[28](https://app.finbar.com/go?id=P149984432)[29](https://app.finbar.com/go?id=P149984433)
[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[12](https://app.finbar.com/go?id=T17158952)[13](https://www.genmab.com/news-insights/stories/delivering-genmabs-next-era-of-sustainable-growth)[14](https://app.finbar.com/go?id=P149984418)[15](https://app.finbar.com/go?id=P149984419)[16](https://app.finbar.com/go?id=P149984420)[17](https://app.finbar.com/go?id=P149984421)[18](https://app.finbar.com/go?id=P149984422)[19](https://app.finbar.com/go?id=P149984423)[20](https://app.finbar.com/go?id=P149984424)[21](https://app.finbar.com/go?id=P149984425)[22](https://app.finbar.com/go?id=P149984426)[23](https://app.finbar.com/go?id=P149984427)[24](https://app.finbar.com/go?id=P149984428)[25](https://app.finbar.com/go?id=P149984429)[26](https://app.finbar.com/go?id=P149984430)[27](https://app.finbar.com/go?id=P149984431)[28](https://app.finbar.com/go?id=P149984432)[29](https://app.finbar.com/go?id=P149984433)[13](https://www.genmab.com/news-insights/stories/delivering-genmabs-next-era-of-sustainable-growth)

## Business segments

Genmab A/S’s 2025 reporting does not identify separately named business or operating segments, describe segment-specific focus areas, or disclose segment revenue contributions. Accordingly, no segment-level percentage breakdown is available; the company’s reported revenue drivers should not be treated as business segments. [30](https://app.finbar.com/go?id=D357473)[6](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231.htm)
[30](https://app.finbar.com/go?id=D357473)[6](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231.htm)

## Company history

Founded in Copenhagen in 1999, Genmab held its initial public offering on the Copenhagen Stock Exchange in 2000. Its first antibody to reach the market was ofatumumab (Arzerra), approved in the United States in 2009 for certain patients with chronic lymphocytic leukemia. In 2010, co-founder Jan van de Winkel became president and CEO, and the company introduced its DuoBody bispecific-antibody technology. [1](https://www.genmab.com/about/our-history) [31](https://www.dnbcarnegie.com/transaction/initial-public-offering-of-genmab-as-dk-dkk-16-billion/) [32](https://ir.genmab.com/static-files/6c7dfba6-7db1-4dba-afc5-c1a5116087cb) [33](https://www.genmab.com/about/executive-committee/jan-van-de-winkel) [34](https://www.us.genmab.com/company/about-us/experience-and-milestones)

A significant commercial milestone came in 2015, when daratumumab (DARZALEX) was approved for multiple myeloma; Genmab receives royalties on the product. Ofatumumab was later approved as KESIMPTA for relapsing forms of multiple sclerosis in 2020. In 2022, TECVAYLI became the first approved therapy made using Genmab’s DuoBody technology, followed by U.S. accelerated approval of epcoritamab (EPKINLY), co-developed with AbbVie, in 2023. [35](https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-approved-by-us-fda-first-human-anti-cd38-monoclonal-antibody-available-for-the-treatment-of-multiple-myeloma) [36](https://app.finbar.com/go?id=P149983109) [37](https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis) [38](https://www.genmab.com/antibody-science/antibody-technology-platforms/duobody) [39](https://www.businesswire.com/news/home/20230518005495/en/EPKINLY%E2%84%A2-epcoritamab-bysp-Approved-by-U.S.-Food-and-Drug-Administration-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adults-with-Relapsed-or-Refractory-RR-Diffuse-Large-B-cell-Lymphoma-DLBCL)

Genmab completed its acquisition of antibody-drug-conjugate developer ProfoundBio in 2024. In 2025, it pursued and completed a tender offer for Merus, expanding its portfolio through another major acquisition. [40](https://ir.genmab.com/news-releases/news-release-details/genmab-completes-acquisition-profoundbio/) [41](https://ir.genmab.com/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and/) [42](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-completion-tender-offer-outstanding-common)
[36](https://app.finbar.com/go?id=P149983109)[1](https://www.genmab.com/about/our-history)[31](https://www.dnbcarnegie.com/transaction/initial-public-offering-of-genmab-as-dk-dkk-16-billion/)[32](https://ir.genmab.com/static-files/6c7dfba6-7db1-4dba-afc5-c1a5116087cb)[33](https://www.genmab.com/about/executive-committee/jan-van-de-winkel)[34](https://www.us.genmab.com/company/about-us/experience-and-milestones)[35](https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-approved-by-us-fda-first-human-anti-cd38-monoclonal-antibody-available-for-the-treatment-of-multiple-myeloma)[37](https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis)[38](https://www.genmab.com/antibody-science/antibody-technology-platforms/duobody)[39](https://www.businesswire.com/news/home/20230518005495/en/EPKINLY%E2%84%A2-epcoritamab-bysp-Approved-by-U.S.-Food-and-Drug-Administration-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adults-with-Relapsed-or-Refractory-RR-Diffuse-Large-B-cell-Lymphoma-DLBCL)[40](https://ir.genmab.com/news-releases/news-release-details/genmab-completes-acquisition-profoundbio/)[41](https://ir.genmab.com/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and/)[42](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-completion-tender-offer-outstanding-common)

## Sources

1. [www.genmab.com](https://www.genmab.com/about/our-history)
2. [www.genmab.com](https://www.genmab.com/antibody-science/antibody-technology-platforms)
3. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149982889)
4. [www.genmab.com](https://www.genmab.com/contact)
5. [www.genmab.com](https://www.genmab.com/about/our-purpose)
6. [www.sec.gov](https://www.sec.gov/Archives/edgar/data/1434265/000143426526000014/gmab-20251231.htm)
7. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17158948)
8. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149983225)
9. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17158950)
10. [www.genmab.com](https://www.genmab.com/investor-relations/annual-report)
11. [ir.genmab.com](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-financial-results-first-half-2026)
12. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17158952)
13. [www.genmab.com](https://www.genmab.com/news-insights/stories/delivering-genmabs-next-era-of-sustainable-growth)
14. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984418)
15. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984419)
16. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984420)
17. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984421)
18. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984422)
19. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984423)
20. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984424)
21. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984425)
22. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984426)
23. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984427)
24. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984428)
25. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984429)
26. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984430)
27. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984431)
28. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984432)
29. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149984433)
30. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=D357473)
31. [www.dnbcarnegie.com](https://www.dnbcarnegie.com/transaction/initial-public-offering-of-genmab-as-dk-dkk-16-billion/)
32. [ir.genmab.com](https://ir.genmab.com/static-files/6c7dfba6-7db1-4dba-afc5-c1a5116087cb)
33. [www.genmab.com](https://www.genmab.com/about/executive-committee/jan-van-de-winkel)
34. [www.us.genmab.com](https://www.us.genmab.com/company/about-us/experience-and-milestones)
35. [www.jnj.com](https://www.jnj.com/media-center/press-releases/darzalex-daratumumab-approved-by-us-fda-first-human-anti-cd38-monoclonal-antibody-available-for-the-treatment-of-multiple-myeloma)
36. [GENMAB A/S — Full financial report (2025 Y)](https://app.finbar.com/go?id=P149983109)
37. [www.novartis.com](https://www.novartis.com/news/media-releases/fda-approves-novartis-kesimpta-ofatumumab-first-and-only-self-administered-targeted-b-cell-therapy-patients-relapsing-multiple-sclerosis)
38. [www.genmab.com](https://www.genmab.com/antibody-science/antibody-technology-platforms/duobody)
39. [www.businesswire.com](https://www.businesswire.com/news/home/20230518005495/en/EPKINLY%E2%84%A2-epcoritamab-bysp-Approved-by-U.S.-Food-and-Drug-Administration-as-the-First-and-Only-Bispecific-Antibody-to-Treat-Adults-with-Relapsed-or-Refractory-RR-Diffuse-Large-B-cell-Lymphoma-DLBCL)
40. [ir.genmab.com](https://ir.genmab.com/news-releases/news-release-details/genmab-completes-acquisition-profoundbio/)
41. [ir.genmab.com](https://ir.genmab.com/news-releases/news-release-details/genmab-acquire-merus-expanding-late-stage-pipeline-and/)
42. [ir.genmab.com](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-completion-tender-offer-outstanding-common)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.